Report Detail

Request for Sample of this report

Other B-cell Non-Hodgkin’s Lymphoma—Market Insights, Epidemiology, and Market Forecast—2028

  • RnM3869816
    • |
  • 24 January, 2020
    • |
  • Global
    • |
  • 287 Pages
    • |
  • DelveInsight
    • |
  • Other

DelveInsight’s ‘B-cell Non-Hodgkin’s Lymphoma—Market Insights, Epidemiology, and Market Forecast—2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-cell NHL in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028
B-cell NHL—Disease Understanding and Treatment Algorithm
NHL is a type of blood cancer that initially started in the white blood cells (WBCs) called lymphocytes, it is also known as non-Hodgkin’s disease. Commonly the NHL occurs from lymph node at one or more places in the body, which can progress through the lymphatic system from one group of lymph nodes to another. It can progress to other lymph tissue, particularly in the bone marrow and spleen, or to lymph nodes in the liver.
NHL represents a heterogeneous group of malignancies of different biology and prognosis. It can occur at any age and are often marked by enlarged lymph nodes, fever, night sweats, and weight loss. There are different types of, and these are divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas and are collectively known as post-transplant lymph proliferative disorders.
B-cells or B lymphocytes help to protect the body against bacteria and viruses by making proteins called antibodies. Most of the cases of NHL are B-cell NHL. The exact cause of NHL is unknown but the factors that can increase the risk of developing the conditions are weakening of immune system, continuous uptake of immunosuppressant medication, and previous exposure of common virus-like Epstein-Barr virus. The diagnosis of NHL is mainly done by carrying out a biopsy. If it is confirmed by biopsy then further it is tested by a blood test, chest X-ray, CT scan, MRI Scan, PET scan, and Lumbar puncture, etc.
On the basis of diagnosis the treatment is done which includes chemotherapy, radiation therapy, targeted therapy, immunotherapy such as monoclonal antibodies, immune checkpoint inhibitors, and CAR T cells, and stem cell transplantation/bone marrow transplantation.
B-cell NHL Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of NHL, Total Incidence cases of B cell-NHL, Gender-specific Incidence of B-cell NHL, Age-specific Incidence of B-cell NHL, Subtype - Specific Incidence of B-cell NHL and Stage-Specific Incidence of B-cell NHL] scenario of B-cell NHL in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.
DelveInsight’s analysts have assessed that the total prevalent population of B-cell NHL in the 7MM was 141,873 in 2017. In addition to this, there was a gender difference in the disease. It was seen that, the B-cell lymphoma cases occurs more frequently in male population as compared to female. In 2017, a more number of males were affected by the disease, i.e., 55% of the B-cell NHL cases in the 7MM, which is equivalent to 78,030 cases in comparison to the females.
B-cell NHL Drug Chapters
The treatment of B-cell NHL is mainly based on the subtype and stage of the disease, according to the subtype and stage of the disease, initial therapy and intensity of treatment taken into consideration. In general, the goal of treatment is to destroy as many lymphoma cells as possible and to induce complete remission. Treatment can also keep non-Hodgkin lymphoma (NHL) in check for many years, even though imaging or other studies show the remaining sites of disease. This situation may be referred to as a “partial remission.”
For patients without symptoms and with indolent subtypes of B-cell NHL, the treatment may be the watch-and-wait approach, meaning treatment is deferred or delayed until signs of disease progression occur. Frequent and careful observation is required so that effective treatment can be started if the disease starts advancing. Some patients have a long-time slow-growing disease, while others have a condition that evolves (transforms) into a more aggressive type of B-cell NHL that requires immediate treatment.
In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell NHL. Although radiation therapy is often neither the sole nor the principal curative therapy, it is an important additional treatment in some cases.
The current treatment approaches include Rituximab based mono and combination therapies, Monoclonal antibodies based regimen except Rituximab, Immune Checkpoint inhibitors, Immunomodulators, Proteasome inhibitors, Kinase inhibitors, CAR-T cell therapies, and Histone deacetylase (HDAC) inhibitors.
The following drugs are approved under abovementioned classes, Brukinsa (Zanubrutinib, a product of BeiGene), Polivy (Polatuzumab vedotin, a product of Hoffmann-La Roche), Venetoclax (ABT199, a product of AbbVie and Roche), Kymriah (tisagenlecleucel, a product of Novartis), Yescarta (Axicabtagene ciloleucel, a product of Gilead Sciences), Aliqopa (Copanlisib, a product of Bayer), Imbruvica (Ibrutinib, a product of Janssen/Pharmacyclics (AbbVie Company)), Zydelig (Idelalisib, a product of Gilead Sciences), Gazyva (Obinutuzumab, a product of Genentech, Roche Group), Zevalin (ibritumomab tiuxetan, a product of Spectrum Pharmaceuticals), Velcade (bortezomib, a product of Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical), Revlimid (lenalidomide, a product of Celgene Corporation) and others.
B-cell NHL Market Outlook
The market size of B-cell NHL in seven major markets (7MM) is estimated to be USD 4,103 million in 2017. The United States accounts for the highest market size of B-cell NHL in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while Spain had the lowest market size of B-cell NHL in 2017.
B-cell NHL Drugs Uptake
With the launch of emerging therapies like Lisocabtagene maraleucel (JCAR017, a product of Bristol-Myers Squibb), which is an anti-CD-19-directed CAR T-cell product administered intravenously in defined composition at a precise dose of CD8 and CD4 CAR T cells which induced durable responses in poor-prognosis patients with R/R aggressive NHL after at least two prior therapies, KTE-X19 (Gilead Sciences), Tafasitamab (MOR208, a product of MorphoSys AG), Tazemetostat (E7438, a product of Epizyme), Abexinostat (Xynomic Pharmaceuticals), Umbralisib (TG Therapeutics), Avelumab (Pfizer/Merck) and others, the market of B-cell NHL is anticipated to change during the forecast period (2019–2028).
Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by DelveInsight’s analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of B-cell NHL will have better management practices.
According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019–2028], and with their anticipated launch, the market size of B-cell NHL will also experience significant growth.
B-cell NHL Report Insights
• Total Incidence of NHL
• Total Incidence cases of B cell-NHL
• Gender-specific Incidence of B-cell NHL
• Age-specific Incidence of B-cell NHL
• Subtype - Specific Incidence of B-cell NHL
• Stage-Specific Incidence of B-cell NHL
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

B-cell NHL Report Key Strengths
• 10–Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

B-cell NHL Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving B-cell NHL market
• Organize sales and marketing efforts by identifying the best opportunities for B-cell NHL market
• To understand the future market competition in the B-cell NHL market.


1. Key Insights

    2. Executive Summary of B-cell NHL

      3. SWOT Analysis for B-cell NHL

        4. B-cell NHL: Patient Share of B-cell NHL at a Glance

        • 4.1. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2017
        • 4.2. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2028
        • 4.3. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2017
        • 4.4. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2028

        5. B-cell NHLs: Market Overview at a Glance

        • 5.1. Total Market Share (%) Distribution of B-cell NHL in 2017
        • 5.2. Total Market Share (%) Distribution of B-cell NHL in 2028

        6. B-cell Non-Hodgkin Lymphoma (NHL): Disease Background and Overview

        • 6.1. Types of B-cell NHL
          • 6.1.1. Diffuse large B-cell lymphoma (DLBCL)
          • 6.1.2. Burkitt Lymphoma (BL)
          • 6.1.3. Mantle Cell Lymphoma (MCL)
          • 6.1.4. Follicular Lymphoma (FL)
          • 6.1.5. Marginal Zone Lymphoma (MZL)
          • 6.1.6. Chronic Lymphocytic Leukemia (CLL) and Small-Cell Lymphocytic Lymphoma (SLL)
        • 6.2. Origin and Pathogenesis of B-cell NHL
          • 6.2.1. Genetic Lesions in the Pathogenesis of B-cell Lymphomas
          • 6.2.2. Microenvironmental Interactions in B-Cell Lymphomas and the Role of the BCR
        • 6.3. Risk Factors for NHL
        • 6.4. Staging for B-cell NHL
          • 6.4.1. Staging of NHL in Adults
          • 6.4.2. Staging of NHL in Children
          • 6.4.3. Staging Systems for Chronic Lymphocytic Lymphoma (CLL)
        • 6.5. Survival Rate for NHL (5-year)
        • 6.6. Diagnosis of NHL
          • 6.6.1. Diagnostic Algorithm for B-cell NHL
          • 6.6.2. Evaluation
          • 6.6.3. Testing Strategies to Diagnose B-cell Lymphomas
          • 6.6.4. Stratification of High-Grade B-cell Lymphomas Using Laboratory Techniques
          • 6.6.5. Summary of Recommendations for Diagnosis and pathology/molecular biology (DLBCL): European Society for Medical Oncology (ESMO)

        7. Epidemiology and Patient Population

        • 7.1. Epidemiology Key Findings
        • 7.2. Assumptions and Rationale: 7MM

        8. Epidemiology Scenario: 7MM

        • 8.1. Total Incidence of NHL in the 7MM
          • 8.1.1. Total Incidence cases of B cell-NHL in the 7MM
          • 8.1.2. Gender-specific Incidence of B-cell NHL in the 7MM
          • 8.1.3. Age-specific Incidence of B-cell NHL in the 7MM
          • 8.1.4. Subtype - Specific Incidence of B-cell NHL in the 7MM
          • 8.1.5. Stage-Specific Incidence of B-cell NHL in the 7MM

        9. United States Epidemiology

        • 9.1. Total Incidence cases of B cell-NHL in the United States
        • 9.2. Age-specific Incidence of B-cell NHL in the United States
        • 9.3. Subtype-Specific Incidence of B-cell NHL in the United States
        • 9.4. Stage-Specific Incidence of B-cell NHL in the United States

        10. EU-5 Country-wise Epidemiology

        • 10.1. Germany Epidemiology
          • 10.1.1. Total Incidence cases of B cell-NHL in Germany
          • 10.1.2. Age-specific Incidence of B-cell NHL in Germany
          • 10.1.3. Subtype-Specific Incidence of B-cell NHL in Germany
          • 10.1.4. Stage-Specific Incidence of B-cell NHL in Germany
        • 10.2. France Epidemiology
          • 10.2.1. Total Incidence cases of B cell-NHL in France
          • 10.2.2. Age-specific Incidence of B-cell NHL in France
          • 10.2.3. Subtype-Specific Incidence of B-cell NHL in France
          • 10.2.4. Stage-Specific Incidence of B-cell NHL in France
        • 10.3. Italy Epidemiology
          • 10.3.1. Total Incidence cases of B cell-NHL in Italy
          • 10.3.2. Age-specific Incidence of B-cell NHL in Italy
          • 10.3.3. Subtype-Specific Incidence of B-cell NHL in Italy
          • 10.3.4. Stage-Specific Incidence of B-cell NHL in Italy
        • 10.4. Spain Epidemiology
          • 10.4.1. Total Incidence cases of B cell-NHL in Spain
          • 10.4.2. Age-specific Incidence of B-cell NHL in Spain
          • 10.4.3. Subtype-Specific Incidence of B-cell NHL in Spain
          • 10.4.4. Stage-Specific Incidence of B-cell NHL in Spain
        • 10.5. United Kingdom Epidemiology
          • 10.5.1. Total Incidence cases of B cell-NHL in the United Kingdom
          • 10.5.2. Age-specific Incidence of B-cell NHL in the United Kingdom
          • 10.5.3. Subtype-Specific Incidence of B-cell NHL in the United Kingdom
          • 10.5.4. Stage-Specific Incidence of B-cell NHL in the United Kingdom

        11. Japan Epidemiology

        • 11.1. Total Incidence cases of B cell-NHL in Japan
        • 11.2. Age-specific Incidence of B-cell NHL in Japan
        • 11.3. Subtype-Specific Incidence of B-cell NHL in Japan
        • 11.4. Stage-Specific Incidence of B-cell NHL in Japan

        12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS)

        • 12.1. Treatment Overview
          • 12.1.1. Factors That Influence Treatment
          • 12.1.2. The International Prognostic Index (IPI)
          • 12.1.3. Treatment Considerations for Children, Adolescents, and Young Adults
        • 12.2. Treatment of B-cell NHL Subtypes
          • 12.2.1. Diffuse Large B-Cell Lymphoma (DLBCL)
          • 12.2.2. Burkitt Lymphoma
          • 12.2.3. Mantle Cell Lymphoma (MCL)
          • 12.2.4. Follicular Lymphoma (FL)
          • 12.2.5. Marginal Zone Lymphoma (MZL)
          • 12.2.6. Small-Cell Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL)

        13. Unmet Needs

          14. Marketed Products

          • 14.1. Brukinsa (Zanubrutinib): BeiGene
            • 14.1.1. Product Description
            • 14.1.2. Regulatory Milestones
            • 14.1.3. Other Developmental Activities
            • 14.1.4. Pivotal Clinical Trials
            • 14.1.5. Ongoing Clinical Trials
          • 14.2. Polivy (Polatuzumab vedotin): Hoffmann-La Roche
            • 14.2.1. Product Description
            • 14.2.2. Regulatory Milestones
            • 14.2.3. Other Developmental Activities
            • 14.2.4. Pivotal Clinical Trials
            • 14.2.5. Ongoing Current Pipeline Activity
          • 14.3. Venetoclax (ABT199): AbbVie and Roche
            • 14.3.1. Product Description
            • 14.3.2. Regulatory Milestones
            • 14.3.3. Other Developmental Activities
            • 14.3.4. Pivotal Clinical Trials
            • 14.3.5. Ongoing Clinical Trials
          • 14.4. Kymriah (tisagenlecleucel): Novartis
            • 14.4.1. Product Description
            • 14.4.2. Regulatory Milestones
            • 14.4.3. Other Developmental Activities
            • 14.4.4. Pivotal Clinical Trials
            • 14.4.5. Ongoing Current Pipeline Activity
          • 14.5. Copiktra (Duvelisib): Verastem
            • 14.5.1. Product Description
            • 14.5.2. Regulatory Milestones
            • 14.5.3. Other Developmental Activities
            • 14.5.4. Pivotal Clinical Trials
          • 14.6. Keytruda (Pembrolizumab): Merck Sharp & Dohme
            • 14.6.1. Product Description
            • 14.6.2. Regulatory Milestones
            • 14.6.3. Pivotal Clinical Trials
            • 14.6.4. Ongoing Current Pipeline Activity
          • 14.7. Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences
            • 14.7.1. Product Description
            • 14.7.2. Regulatory Milestones
            • 14.7.3. Other Developmental Activities
            • 14.7.4. Pivotal Clinical Trials
            • 14.7.5. Ongoing Current Pipeline Activity
          • 14.8. Aliqopa (Copanlisib; BAY 80-6946): Bayer
            • 14.8.1. Product Description
            • 14.8.2. Regulatory Milestones
            • 14.8.3. Other Developmental Activities
            • 14.8.4. Pivotal Clinical Trials
            • 14.8.5. Ongoing Current Pipeline Activity
          • 14.9. Calquence (Acalabrutinib): AstraZeneca
            • 14.9.1. Product Description
            • 14.9.2. Regulatory Milestones
            • 14.9.3. Other Dvelopmental Activities
            • 14.9.4. Pivotal Clinical Trials
            • 14.9.5. Ongoing Clinical Trials
          • 14.10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
            • 14.10.1. Product Description
            • 14.10.2. Regulatory Milestones
            • 14.10.3. Other Developmental Activities
            • 14.10.4. Pivotal Clinical Trials
            • 14.10.5. Ongoing Current Pipeline Activity
          • 14.11. Zydelig (Idelalisib): Gilead Sciences
            • 14.11.1. Product Description
            • 14.11.2. Regulatory Milestones
            • 14.11.3. Other Developmental Activities
            • 14.11.4. Pivotal Clinical Trials
            • 14.11.5. Ongoing Current Pipeline Activity
          • 14.12. Gazyva (Obinutuzumab, GA-101): Genentech (Roche Group)
            • 14.12.1. Product Description
            • 14.12.2. Regulatory Milestones
            • 14.12.3. Other Developmental Activities
            • 14.12.4. Pivotal Clinical Trials
            • 14.12.5. Ongoing Current Pipeline Activity
          • 14.13. Revlimid (lenalidomide): Celgene Corporation
            • 14.13.1. Product Description
            • 14.13.2. Regulatory Milestones
            • 14.13.3. Other Developmental Activities
            • 14.13.4. Pivotal Clinical Trials
            • 14.13.5. Ongoing Clinical Trials
          • 14.14. Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical
            • 14.14.1. Product Description
            • 14.14.2. Regulatory Milestones
            • 14.14.3. Other Developmental Activities
            • 14.14.4. Pivotal Clinical Trials
            • 14.14.5. Ongoing Current Pipeline Activity
          • 14.15. Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals
            • 14.15.1. Product Description
            • 14.15.2. Regulatory Milestones
            • 14.15.3. Other Developmental Activities
            • 14.15.4. Pivotal Clinical Trials
          • 14.16. Torisel: Pfizer
            • 14.16.1. Product Description
            • 14.16.2. Regulatory Milestones
            • 14.16.3. Pivotal Clinical Trials

          15. Emerging Therapies

          • 15.1. Key Cross
          • 15.2. Tafasitamab (MOR208; formerly XmAb 5574): MorphoSys AG
            • 15.2.1. Product Description
            • 15.2.2. Other Developmental Activities
            • 15.2.3. Clinical Development
            • 15.2.4. Safety and Efficacy
          • 15.3. Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb
            • 15.3.1. Product Description
            • 15.3.2. Other Developmental Activities
            • 15.3.3. Clinical Development
            • 15.3.4. Safety and Efficacy
          • 15.4. Enzastaurin Hydrochloride (DB102): Denovo Biopharma
            • 15.4.1. Product Description
            • 15.4.2. Other Developmental Activities
            • 15.4.3. Clinical Development
            • 15.4.4. Safety and Efficacy
          • 15.5. Avelumab (Bavencio): Pfizer/Merck
            • 15.5.1. Product Description
            • 15.5.2. Other Developmental Activities
            • 15.5.3. Clinical Development
          • 15.6. Umbralisib (TG-1202): TG Therapeutics
            • 15.6.1. Product Description
            • 15.6.2. Other Developmental Activities
            • 15.6.3. Clinical Development
            • 15.6.4. Safety and Efficacy

          16. B-cell NHL: Seven Major Market Analysis

          • 16.1. Key Findings
          • 16.2. Total Market Size of B-cell NHL in the 7MM
          • 16.3. Market Size of B-cell NHL by Therapeutic Class in the 7MM

          17. Market Outlook: 7MM

            18. United States Market Size

            • 18.1. Total Market size of B-cell NHL in the United States
            • 18.2. Market Size of B-cell NHL by Line of Therapies in the US

            19. EU-5 Market Size

            • 19.1. Germany Market Size
              • 19.1.1. Total Market size of B-cell NHL in Germany
              • 19.1.2. Market Size of B-cell NHL by Line of Therapies in Germany
            • 19.2. France Market Size
              • 19.2.1. Total Market size of B-cell NHL in France
              • 19.2.2. Market Size of B-cell NHL by Therapies in France
            • 19.3. Italy Market Size
              • 19.3.1. Total Market size of B-cell NHL in Italy
              • 19.3.2. Market Size of B-cell NHL by Line of Therapies in Italy
            • 19.4. Spain Market Size
              • 19.4.1. Total Market size of B-cell NHL in Spain
              • 19.4.2. Market Size of B-cell NHL by Line of Therapies in Spain
            • 19.5. United Kingdom Market Size
              • 19.5.1. Total Market size of B-cell NHL in the United Kingdom
              • 19.5.2. Market Size of B-cell NHL by Line of Therapies in the United Kingdom

            20. Japan Market Size

            • 20.1. Total Market size of B-cell NHL in Japan
            • 20.2. Market Size of B-cell NHL by Therapies in Japan

            21. Market Access and Reimbursement Scenario of B-cell NHL Therapies

            • 21.1. CAR-T cell Therapies

            22. Market Drivers

              23. Market Barriers

                24. Appendix

                • 24.1. Bibliography
                • 24.2. Report Methodology

                25. Disclaimer

                  26. DelveInsight Capabilities

                    27. About DelveInsight

                    Summary:
                    Get latest Market Research Reports on B-cell Non-Hodgkin’s Lymphoma. Industry analysis & Market Report on B-cell Non-Hodgkin’s Lymphoma is a syndicated market report, published as B-cell Non-Hodgkin’s Lymphoma—Market Insights, Epidemiology, and Market Forecast—2028. It is complete Research Study and Industry Analysis of B-cell Non-Hodgkin’s Lymphoma market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                    Last updated on

                    REPORT YOU MIGHT BE INTERESTED

                    Purchase this Report

                    		$6,250.00
                    		$12,500.00
                    		$18,750.00
                    		5,075.00
                    		10,150.00
                    		15,225.00
                    		6,006.25
                    		12,012.50
                    		18,018.75
                    		972,687.50
                    		1,945,375.00
                    		2,918,062.50
                    		540,937.50
                    		1,081,875.00
                    		1,622,812.50
                    Credit card Logo
                    Sample Question Discount Download PDF

                    Related Reports

                    Reason to Buy

                    • Trusted By Leaders

                      Top executives from leading companies purchase research reports from us. 

                    • Shop With Confidence

                      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

                    • Customer Centric

                      Need assistance related to your research requirements? We are just a phone call or an email away.

                    • Personalized Solutions

                      Our experienced research specialists are here to help you locate the right reports for your need.

                    • Secure Checkout

                      Shop without being worried about safety & security of your transactions.
                      •

                    Request for Sample of this report

                    Reports and Markets

                    mcafree

                    Contact Us

                    +1-352-353-0818 (US)

                    info@reportsandmarkets.com

                    Support

                    EMAIL US

                    Newsletter

                    KEEP UP TO DATE ON ALL THE LATEST REPORTS


                    maxmind_logo